Search

Your search keyword '"Kameda, Hideto"' showing total 12 results
Start Over Author "Kameda, Hideto" Journal rheumatology
12 results on '"Kameda, Hideto"'

1. E089 Effect of secukinumab on radiographic progression and inflammation in sacroiliac joints and spine in patients with non-radiographic axial spondyloarthritis: 2-year imaging outcomes from a Phase III randomised trial

Author

Marzo-Ortega, Helena, primary, Braun, Juergen, additional, Blanco, Ricardo, additional, Gensler, Lianne S, additional, van den Bosch, Filip, additional, Hall, Stephen, additional, Kameda, Hideto, additional, Poddubnyy, Denis, additional, van de Sande, Marleen G H, additional, van der Heidje, Désirée, additional, Zhuang, Tingting, additional, Stefanska, Anna, additional, Readie, Aimee, additional, Richards, Hanno, additional, and Deodhar, Atul, additional

Published
2023
Full Text
View/download PDF

2. OA34 Post-hoc analysis of spinal MRI SPARCC inflammation scores in patients with radiographic axial spondyloarthritis treated with ixekizumab: results from the COAST-V study at week 16

Author

Marzo-Ortega, Helena, primary, Tsai, Wen-Chan, additional, Kameda, Hideto, additional, Konomi, Ayako, additional, Bradley, Andrew J, additional, Ng, Khai Jing, additional, Schymura, Yves, additional, Liu-Leage, Soyi, additional, Maksymowych, Walter P, additional, and Østergaard, Mikkel, additional

Published
2022
Full Text
View/download PDF

4. Branched chain amino acids in the treatment of polymyositis and dermatomyositis: a phase II/III, multi-centre, randomized controlled trial

Author

Kimura, Naoki, primary, Kawahara, Takuya, additional, Uemura, Yukari, additional, Atsumi, Tatsuya, additional, Sumida, Takayuki, additional, Mimura, Toshihde, additional, Kawaguchi, Yasushi, additional, Amano, Hirofumi, additional, Iwasaki, Yukiko, additional, Kaneko, Yuko, additional, Matsui, Toshihiro, additional, Muro, Yoshinao, additional, Imura, Yoshitaka, additional, Kanda, Takashi, additional, Tanaka, Yoshiya, additional, Kawakami, Atsushi, additional, Jinnin, Masatoshi, additional, Ishii, Tomonori, additional, Hiromura, Keiju, additional, Miwa, Yusuke, additional, Nakajima, Hiroshi, additional, Kuwana, Masataka, additional, Nishioka, Yasuhiko, additional, Morinobu, Akio, additional, Kameda, Hideto, additional, and Kohsaka, Hitoshi, additional

Published
2022
Full Text
View/download PDF

6. Sarilumab monotherapy vs sarilumab and methotrexate combination therapy in patients with rheumatoid arthritis.

Author

Burmester, Gerd R, Bykerk, Vivian P, Buch, Maya H, Tanaka, Yoshiya, Kameda, Hideto, Praestgaard, Amy, Hoogstraten, Hubert van, Fernandez-Nebro, Antonio, and Huizinga, Thomas

Subjects
THERAPEUTIC use of monoclonal antibodies, DRUG efficacy, STATISTICS, C-reactive protein, GLUCOCORTICOIDS, COMBINATION drug therapy, HEMOGLOBINS, CONFIDENCE intervals, ORAL drug administration, VISUAL analog scale, METHOTREXATE, COMPARATIVE studies, RHEUMATOID arthritis, DESCRIPTIVE statistics, QUESTIONNAIRES, DATA analysis
Abstract

Objective Sarilumab, as monotherapy or in combination with conventional synthetic DMARDs, such as MTX, has demonstrated improvement in clinical outcomes in patients with RA. The primary objective of this post hoc analysis was to compare the efficacy of sarilumab (200 mg every 2 weeks) monotherapy (MONARCH study) with that of sarilumab and MTX combination therapy (MOBILITY study) at week 24. Methods The endpoints assessed were mean change from baseline in the Clinical Disease Activity Index (CDAI), 28-joint Disease Activity using CRP (DAS28-CRP), CRP, haemoglobin (Hb), pain visual analogue scale (VAS) and Functional Assessment of Chronic Illness Therapy (FACIT)–Fatigue. Least square (LS) mean change from baseline (95% CI) at week 24 for all endpoints was compared between the treatment arms for adjusted comparisons. Results This analysis included 184 patients on sarilumab monotherapy and 399 patients on sarilumab plus MTX. Differences (P  < 0.05) were observed in ethnicity, region, body mass index group, rheumatoid factor, anti-cyclic citrullinated peptide antibodies, swollen joint count, CRP, CDAI and oral glucocorticoid use between these treatment groups. After adjusting for these differences in a mixed-effect model repeated measure, LS mean change from baseline for all assessments was similar between the treatment groups with overlapping CIs: CDAI, −28.79 vs −26.21; DAS28-CRP, −2.95 vs −2.81; CRP, −18.31 vs −16.46; Hb, 6.59 vs 8.09; Pain VAS, −33.62 vs −31.66; FACIT-Fatigue, 9.90 vs 10.24. Conclusion This analysis demonstrated that the efficacy of sarilumab monotherapy was similar to that of sarilumab and MTX combination therapy. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

7. P190 Secukinumab improves back pain, morning stiffness, fatigue and physical function in tumour necrosis factor inhibitor-naive patients with non-radiographic axial spondyloarthritis: results from a randomised controlled Phase 3 study

Author

Marzo-Ortega, Helena, primary, Deodhar, Atul, additional, Blanco, Ricardo Alonso, additional, Kameda, Hideto, additional, Kivitz, Alan, additional, Poddubnyy, Denis, additional, Magrey, Marina N, additional, Wang, Jianyuan, additional, Haemmerle, Sibylle, additional, Shete, Abhijit, additional, and Braun, Jürgen, additional

Published
2021
Full Text
View/download PDF

10. Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study

Author

Kameda, Hideto, primary, Takeuchi, Tsutomu, additional, Yamaoka, Kunihiro, additional, Oribe, Motohiro, additional, Kawano, Mitsuhiro, additional, Zhou, Yijie, additional, Othman, Ahmed A, additional, Pangan, Aileen L, additional, Kitamura, Susumu, additional, Meerwein, Sebastian, additional, and Tanaka, Yoshiya, additional

Published
2020
Full Text
View/download PDF

11. Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1)

Author

Chandran, Vinod, primary, van der Heijde, Désirée, additional, Fleischmann, Roy M, additional, Lespessailles, Eric, additional, Helliwell, Philip S, additional, Kameda, Hideto, additional, Burgos-Vargas, Ruben, additional, Erickson, Janelle S, additional, Rathmann, Suchitrita S, additional, Sprabery, Aubrey Trevelin, additional, Birt, Julie A, additional, Shuler, Catherine L, additional, and Gallo, Gaia, additional

Published
2020
Full Text
View/download PDF

12. IgG4-positive multi-organ lymphoproliferative syndrome manifesting as chronic symmetrical sclerosing dacryo-sialadenitis with subsequent secondary portal hypertension and remarkable IgG4-linked IL-4 elevation

Author

Suzuki, Katsuya, Tamaru, Jun-ichi, Okuyama, Ayumi, Kameda, Hideto, Amano, Koichi, Nagasawa, Hayato, Nishi, Eiko, Yoshimoto, Keiko, Setoyama, Yumiko, Kaneko, Keiko, Osada, Hisato, Honda, Norinari, Sasaki, Yasutsuna, Itoyama, Shinji, Tsuzaka, Kensei, and Takeuchi, Tsutomu

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results